[HTML][HTML] Advances in neoadjuvant therapy for resectable pancreatic cancer over the past two decades
AGM Taboada, PL Lominchar, LM Roman… - Annals of Hepato …, 2021 - ncbi.nlm.nih.gov
In the last two decades, pancreatic cancer has been undergoing important changes in its
perioperative management due to the great interest in multidisciplinary management and …
perioperative management due to the great interest in multidisciplinary management and …
[HTML][HTML] Comprehensive multimodal management of borderline resectable pancreatic cancer: Current status and progress
HY Wu, JW Li, JZ Li, QL Zhai, JY Ye… - World Journal of …, 2023 - ncbi.nlm.nih.gov
Borderline resectable pancreatic cancer (BRPC) is a complex clinical entity with specific
biological features. Criteria for resectability need to be assessed in combination with tumor …
biological features. Criteria for resectability need to be assessed in combination with tumor …
Extracellular matrix composition modulates the responsiveness of differentiated and stem pancreatic cancer cells to lipophilic derivate of gemcitabine
S Forciniti, E Dalla Pozza, MR Greco… - International journal of …, 2020 - mdpi.com
Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease.
Gemcitabine (GEM) is used as the gold standard drug in PDAC treatment. However, due to …
Gemcitabine (GEM) is used as the gold standard drug in PDAC treatment. However, due to …
Prognostic value of perioperative serum low-density lipoprotein cholesterol level for postoperative prognosis of pancreatic cancer: a retrospective study
H Wang, Y Li, J Huang, Y Ma, S Lyu, R Lang - Lipids in Health and …, 2023 - Springer
Background As a common malignant tumour, pancreatic cancer (PC) has the worst clinical
outcome. Early evaluation of the postoperative prognosis has certain clinical value. Low …
outcome. Early evaluation of the postoperative prognosis has certain clinical value. Low …
Differences in receipt of multimodality therapy by race, insurance status, and socioeconomic disadvantage in patients with resected pancreatic cancer
Abstract Background and Methods Racial and socioeconomic disparities in receipt of
adjuvant chemotherapy affect patients with pancreatic cancer. However, differences in …
adjuvant chemotherapy affect patients with pancreatic cancer. However, differences in …
Feasibility, Safety, and Efficacy of Aggressive Multimodal Management of Elderly Patients With Pancreatic Ductal Adenocarcinoma
Objective: To evaluate the safety and efficacy of neoadjuvant therapy (NAT), followed by
surgical resection in patients with pancreatic ductal adenocarcinoma (PDAC) aged≥ 75 …
surgical resection in patients with pancreatic ductal adenocarcinoma (PDAC) aged≥ 75 …
[PDF][PDF] Prognostic value of albumin-bilirubin score in pancreatic cancer patients after pancreatoduodenectomy with liver metastasis following radiofrequency ablation
L Zhang, X Zhang, B Wu, X Han, C Guo… - Pathology and …, 2023 - por-journal.com
Objective: The current study aimed to investigate the prognostic value of albumin-bilirubin
(ALBI) score in predicting clinical outcomes of pancreatic cancer patients after …
(ALBI) score in predicting clinical outcomes of pancreatic cancer patients after …
Differences in receipt of multimodality therapy by race, insurance status, and socioeconomic disadvantage in patientswith resected pancreatic cancer
Background and Methods: Racial and socioeconomic disparities in receipt ofadjuvant
chemotherapy affect patients with pancreatic cancer. However, differencesin receipt of …
chemotherapy affect patients with pancreatic cancer. However, differencesin receipt of …